Please assess the completion status of the following clinical trial:

Trial Title: Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Subjects must meet ACR criteria for diagnosis of RA for at least 3 months, must meet ACR Functional Class I, II or III (1992 criteria) and must have a confirmed diagnosis of active moderate to severe rheumatoid arthritis as defined by 6 or more swollen joints and 9 or more tender joints;~* must also have DAS of 3.2 or greater at study entry,~* normal laboratory parameters and ESR \>20,~* satisfactory response or intolerance to one or more prior DMARDs and~* be willing and able to give informed consent.~Exclusion:~* Previous treatment with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibodies resulting in persistent CD4 lymphopenia,~* history of acute inflammatory joint disease other than RA,~* prior treatment with cyclophosphamide or chlorambucil,~* prior treatment with intravenous immunoglobulin within 70 days,~* history of malignant lymphoma,~* history of uncontrolled diabetes,~* unstable ischemic heart disease,~* active inflammatory bowel disease,~* active peptic ulcer disease or stroke,~* positive HIV status,~* positive serology for Hepatitis B or C,~* no previous history of tuberculosis or listeria infection,~* no previous history of cancer other than successfully treated skin cancer;~* women can not be pregnant or be breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).